← Back to Clinical Trials
Recruiting NCT05316805

China Type II Inflammatory Skin Disease Clinical Research and Standardized Diagnosis and Treatment Project

Trial Parameters

Condition Atopic Dermatitis Eczema
Sponsor Peking University First Hospital
Study Type OBSERVATIONAL
Phase N/A
Enrollment 100,000
Sex ALL
Min Age N/A
Max Age N/A
Start Date 2021-08-31
Completion 2031-12-31

Brief Summary

In order to further improve the diagnosis and treatment level of type 2 inflammatory skin diseases, the National Clinical Center for Skin and Immune Diseases established a standardized diagnosis and treatment center for type 2 inflammatory skin diseases to systematically and effectively understand the current treatment status of patients with type 2 inflammatory skin diseases, as well as the efficacy and safety of various treatment methods during practices, so as to further improve the diagnosis and treatment level of type 2 inflammatory skin diseases and help patients with type 2 inflammatory skin diseases.

Eligibility Criteria

Inclusion Criteria: 1. Patients from the medical units that has passed the data review of the National Clinical Center for Skin and Immune Diseases (see the study sites for data collection for details); 2. patients diagnosed with type 2 inflammatory skin diseases (dermatitis/eczema, urticaria, pemphigoid, prurigo nodularis). Exclusion Criteria: 1. patients who fail to provide informed consent form; 2. patients who cannot complete the questionnaire independently or under the guidance of investigators

Related Trials